BioCentury-BayHelix China Healthcare Summit Schedule
The BioCentury-BayHelix China Healthcare Summit, launched in 2014 in Shanghai, is the place to pressure test your cross-border strategy and build C-level relationships.
Schedule subject to change.
Schedule
GENE & CELL THERAPY
9:00 AM - Kanglin Biotech Co. Ltd.
9:15 AM - Shanghai UniXell Biotechnology Co. Ltd.
CANCER
9:30 AM - MediLink Therapeutics (Suzhou) Co. Ltd.
9:45 AM - Innovent Biologics Inc.
10:00 AM - Abbisko Therapeutics Co. Ltd.
10:15 AM - Cothera Biosciences Inc.
10:30 AM - GeneQuantum Healthcare (Suzhou) Co. Ltd.
10:45 AM - DotBio Pte. Ltd.
11:00 AM - Impact Therapeutics Inc.
HOT TOPICS
11:15 AM - CBC HIP
11:30 AM - Evotec SE
siRNA THERAPEUTICS
1:00 PM - Pramomolecular GmbH
1:15 PM - SynerK Inc.
1:30 PM - Brii Biosciences Ltd.
NEUROLOGY, PSYCHIATRY & OPHTHALMOLOGY
1:45 PM - AffaMed Therapeutics (Shanghai) Co. Ltd.
2:00 PM - Aprinoia Therapeutics Inc.
2:15 PM - Zhaoke Ophthalmology Ltd.
2:30 PM - Genuv Inc.
CANCER
2:45 PM - Enterome S.A.
3:00 PM - CStone Pharmaceuticals Co. Ltd.
3:15 PM - Antengene Corp. Ltd.
3:30 PM - Overland Pharmaceuticals Inc.
3:45 PM - Laekna Inc.
HOT TOPICS
4:00 PM - Galapagos N.V.
4:15 PM - HitGen Inc.
4:30 PM - WuXi Biologics Inc.
4:45 PM - Guardant Health Inc.
5:00 PM - Zhongjing Pukang (Beijing) Pharmaceutical Technology Co. Ltd.
Despite global tensions, innovative assets from China are attracting deals with the West and provide China biopharmas with a path to maximize the impact of their science and technology. BioCentury's 3nd annual China Summit "Scene Setter" panel brings together industry leaders to examine what innovation strengths in China are driving the growth of cross-border dealmaking with the West.
Times are tough. From the global bear market to rising geopolitical and regulatory risks, biotechs CEOs and investors are navigating an increasingly difficult financial landscape. But savvy leaders are preparing now for better times. How can you best manage down-rounds, creative financing structures, or partnerships to extend your cash runway today? Which venue will break out first, HKEX or NASDAQ? What lessons have been learned from biotechs that have raised recent follow-ons? How do biotechs manage geopolitical risks in the current climate? The China Summit's annual Capital Market Showcase again brings investors, bankers, and CEOs to share thoughtful approaches to major industry challenges.
As China innovators face new challenges, what steps must be taken to navigate the industry's first bear market, pricing pressure on innovation, and geopolitical tension? In this fireside chat, the leaders of China's two biopharma associations discuss a path forward for China innovation and cross-border collaboration.
As China biotechs become an innovation engine for the global industry, the mandate is clear: R&D leaders must generate a portfolio of first- or best-in-class assets to land the right global partner and create value. In the Summit's 8th R&D Roundtable, "Scientist CEOs" and Heads of R&D discuss how their strategy is evolving to meet this high bar.
As new technologies emerge and populations age in China and the West, precision medicine will increasingly rely on new and sensitive diagnostics to select or stratify patients for the right therapies. In a era of growing pricing control, how do innovators tackle the challenge of market entry and adoption, while demonstrating long-term clinical value for patients and benefits for the healthcare system.
For its third China medtech report, Insights Partner McKinsey & Company assesses key trends in the China Medtech market and emerging models for value creation. Advanced access to McKinsey's report will be available exclusively to all China Summit delegates.
While local innovation is demonstrating unique value propositions, an increasingly challenging market environment calls for higher quality, agility, and industry collaborations to merge complementary capabilities. Leading medtech multinationals also play a critical role in upgrading the innovation ecosystem. In this panel discussion, industry leaders and investors discuss the path forward for medtech partnerships and emerging investment opportunities.
Regulators everywhere are aligned: Multiregional clinical trials are required for approval in key markets. As China biotechs look to globalize, they must chart a path to clinical trials in the U.S. and Europe. In this session, industry KOLs discuss how to generate data and accelerate development via a global strategy.
For more than 40 years, Dr. Samuel Waksal, Chairman and CEO of Graviton Biosciences, has been founding biotech companies, ranging from ImClone to Kadmon, finding billion-dollar drugs, including Erbitux and Cyramza, and achieving multi-billion-dollar exits to buyers like Bristol-Myers and Sanofi. Graviton has found innovation for its ROCK2 platform in China, obtaining ex-China rights to GV101 from Beijing Tide Pharmaceutical in 2021. And alumni from Waksal's many ventures have become biopharma leaders in China. To close the first day of the Summit, Dr. Waksal reflects on the closing of the innovation gap between China and the West and what he expects to see in the future.